Results 31 to 40 of about 1,228 (155)

Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis [PDF]

Brazilian Journal of Infectious Diseases
The aim of this study was to compare the in vitro activity of delafloxacin with other fluoroquinolones against bacterial pathogens recovered from inpatients with osteomyelitis, Acute Bacterial Skin and Skin-Structure Infections (ABSSSI).
Ághata Cardoso da Silva Ribeiro, Fernanda Fernandes Santos, Tiago Barcelos Valiatti, Michael Henrique Lenzi, Ingrid Nayara Marcelino Santos, Raíssa Fidelis Baêta Neves, Ikechukwu Benjamin Moses, Jaqueline Pilon de Meneses, Renata Gebara de Grande Di Sessa, Mauro José Salles, Ana Cristina Gales   +10 more
doaj   +2 more sources

Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials

Infection and Drug Resistance, 2019
Shao-Huan Lan,1 Chih-Cheng Lai,2 Li-Chin Lu,3 Shen-Peng Chang,4 Hui-Ting Huang41School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, People’s Republic of China; 2Department of Intensive Care Medicine, Chi Mei Medical
Lan SH, Lai CC, Lu LC, Chang SP, Huang HT   +4 more
doaj   +1 more source

Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia

Expert Review of Anti-infective Therapy, 2021
Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.The present narrative review summarizes the available data on the use of ...
Bassetti, Matteo, Melchio, Monica, Giacobbe, Daniele Roberto   +2 more
openaire   +3 more sources

Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin

Pharmaceutics, 2020
Delafloxacin (DFL) is a novel potent and broad-spectrum fluoroquinolone group of antibiotics effective against both Gram-positive and negative aerobic and anaerobic bacteria.
Md. Khalid Anwer, Muzaffar Iqbal, Magdy M. Muharram, Muqtader Mohammad, Essam Ezzeldin, Mohammed F. Aldawsari, Ahmed Alalaiwe, Faisal Imam   +7 more
doaj   +2 more sources

Delafloxacin: An Improved Fluoroquinolone Developed through Advanced Molecular Engineering

Future Microbiology, 2018
The emergence of antimicrobial resistance threatens current clinical practice across a range of infection types. Delafloxacin, a non-zwitterionic fluoroquinolone recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections, has been developed to address some of these challenges.
Bassetti M., Righi E., Pecori D., Tillotson G.   +3 more
openaire   +4 more sources

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties [PDF]

Infectious Diseases and Therapy, 2018
Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from currently marketed fluoroquinolones with the absence of a protonatable substituent conferring a weakly acidic character to the molecule. This property results in increased intracellular penetration and enhanced bactericidal activity under acidic ...
Jorgensen, Sarah C. J., Mercuro, Nicholas J., Davis, Susan L., Rybak, Michael J.   +3 more
openaire   +4 more sources

Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicate Pseudomonas aeruginosa in cystic fibrosis [PDF]

Respiratory Medicine Case Reports
Prompt eradication of Pseudomonas aeruginosa following isolation in sputum samples is a fundamental part of therapy in people with cystic fibrosis in order to prevent chronic infection. Whilst multiple eradication regimens exist, none have been proven to
Michael Kevin Dooney, Tarek Saba, Natasha Pickering, Mohamed Etumi   +3 more
doaj   +2 more sources

In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires’ disease

International Journal of Infectious Diseases
Objectives: Delafloxacin is a fourth-generation fluoroquinolone that is currently approved in Europe and the United States for bacterial infections of the skin and skin structures and for community-acquired pneumonia, including cases where it is caused ...
Roger Cortès-Tarragó, Elisenda Arqué, Lluc Vinyeta, Maria Basart Altieri, Sarahi Marieliza Elizondo, Nieves Sopena, Esteban Reynaga, Javier Díez de los Ríos, Sara Quero, Noemí Párraga-Niño, Luisa Pedro-Botet   +10 more
doaj   +2 more sources

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species

Microbiology Spectrum, 2022
The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested
Yingying Kong, Chao Li, Gangfeng Li, Ting Yang, Mohamed S. Draz, Xinyou Xie, Jun Zhang, Zhi Ruan   +7 more
doaj   +1 more source

Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis

The Clinical Respiratory Journal, 2021
Introduction Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent.
Beverley Cherie Millar, John McCaughan, Jacqueline C. Rendall, John E. Moore   +3 more
doaj   +1 more source